aap Reports EUR 6.5 Million in Sales (+13%) and an increased EBITDA of EUR 0.8 Million (Q1 2010: EUR 0.2 Million)

aap Implantate AG, a medical technology company listed in the Prime Standard segment of the Frankfurt Stock Exchange, achieved sales totaling EUR 6.5 million (previous year: EUR 5.8 million) in the first three months of the financial year 2011. Its EBITDA was EUR 0.8 million (previous year: EUR 0.2 million).

In EUR million Q1/2011 Q1/2010 Change
Sales 6.5 5.8 13%
EBITDA 0.8 0.2 >100%
EBIT 0.1 -0.5 n. a.
Cash-EBIT -0.5 -1.1 n. a.
EBT -0.1 -0.7 n. a.
In EUR million 31/3/2011 31/12/2010 Change
Equity (equity ratio) 44.7 (71%) 44.9 (70%) -0.5%
Balance sheet total 63.4 63.6 -0.2%
Employees 250 256 -2%



In the first quarter of 2011 the Group`s EBIT amounted to EUR 0.1 million (previous year: EUR  -0.5 million). Group EBT was EUR -0.1 million (previous year: EUR -0.7 million). On a balance sheet total of EUR 63.4 million (Dec. 31, 2010: EUR 63.6 million) the equity ratio was 71 percent.

The main focal points of the corporate strategy in 2011 are the trauma and cement & cementing techniques product groups including the integration of infection care into these segments as well as the continued focus on customers, costs and cash. aaps financial goal is to achieve a positive Cash-EBIT (EBIT excluding internally produced and capitalized assets and respective depreciation) by launching new and innovative products such as the WSG-product line, license business deals, new OEM contracts and as well as through increased direct sales. Thereby, aap wants to continue the positive trend of 2010 and generate a profitable growth in 2011.

aap Implantate AG`s first quarter 2011 results in full are available for download at www.aap.de.


aap Implantate AG (ISIN DE0005066609)

- Prime Standard/Regulated Market - All German stock markets -

aap is a medical technology company that develops, manufactures and markets biomaterials and implants for the areas Ortho/Trauma/Spine. Its product portfolio includes bone cements, bone graft substitutes, antibiotic carriers, and implants for fracture healing and joint replacement. In addition to its Berlin HQ the Company has sites in Dieburg near Frankfurt am Main and Nijmegen in the Netherlands. aap Implantate AG stock has been listed in the Prime Standard segment of the Frankfurt Stock Exchange since May 16, 2003.

For inquiries please contact:

aap Implantate AG, Nanette Huedepohl, Head of Corporate Communications, Lorenzweg 5, 12099 Berlin, Germany, Tel.:  +49 30 7501 9133, fax: +49 30 7501 9290, n.huedepohl@aap.de

For more details please visit www.aap.de

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: aap Implantate AG via Thomson Reuters ONE

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here